VirtualScopics — Shareholder Meeting (May 2011)
42 slides from VirtualScopics's shareholder meeting presentation, May 24, 2011
Slide 1: Annual Stockholders' Meeting
a ¥ VIRTUALSCOPICS | Annual Stockholders’ Meeting W, 4 May 24, 2011
Slide 2: Presentation Overview
Presentation Overview L # Vint ALScOPICS
Slide 3: Meeting agenda: director election and auditor ratification
Dan Kerpelman Robert Klimasewski Norman Mintz Charles Ph Terence We atify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended December 31, 2011 OMT RTUALSCOPICS Brow mere Moe fv
Slide 4: Presentation Overview
Presentation Overview L # Vint ALScOPICS
Slide 5: Safe Harbor
3 SAFEHARBOR oO iT] This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance,
Slide 6: Building for the Future: Company and Strategic Overview
Building for the Future Company and Strategic Overview Jeff Markin President and CEO Molly Henderson Chief Business and Financial Officer
Slide 7: Focus for today's discussion
Focus for today’s discussion Jeff Markin, Chief Executive Officer -— * About VirtualScopics * Foundation built for success * Building for the future + 2011 Imperatives Molly Henderson, Chief Business & Financial Officer * Financial review * Personalized medicine application overview * Financial mark
Slide 8: Company Mission
Company Mission Oo Vv Our mission is to improve the lives of those impacted by disease and disability ————E a e VIRTUALSCOPICS
Slide 9: VirtualScopics
VirtualScopics VirtualScopics is a leading provider of quantitative imaging for clinical trials | Key Company Highlights. * Integrated solution delivered as a series of services that manage imaging trials from inception to FDA submission. + Highly automated quantitative analysis vs. conventional qua
Slide 10: Therapeutic Areas
Therapeutic Areas a O | AA Oey Vasc Partin (OCEMRL OCCT) Central Nervous System PAG Voume, ra preenyral Factor Peer that inure orgie
Slide 11: Core Competencies
Core Competencies quantify change in biological structures and processes through the use of medical imaging and imaging science To manage and process very large quantities of information quickly and efficiently in a flexible and transparent manner ‘ a VIRTUALSCOPICS
Slide 12: Expertise in imaging systems and science
Expertise in imaging systems and Imaging protocol design Expertise in image acquisition ‘quality control Imaging Science Expertise in image-based biomarkers. InOA, RA, oncology.cte. | Blomarker relevance to disease ‘progression Software Medicine Image Analy: a Se. ¥ VIRTUALSCOPICS
Slide 13: Benefits: reduced subjects, accelerated time to market
Reduced number of subjects + Higher precision = fewer patients + Fewer patients = lower trial costs Accelerated time to market + Smaller trial sizes = quicker enrollment and faster sults, + Algorithm driven analysis yields results faster than radiologists driven analysis Better information for Go-No
Slide 14: Strong foundation to build upon!
Strong foundation to build upon! A Study Experience | Financial Strength Employment & Leadership ¥ VIRTUALSCOPICS
Slide 15: Study Experience
Study Experience Phase1 Phase2 Phase3 Phase 4 Greater than half the studies we have conducted are Phase 2/3
Slide 16: Financial Strength
Financial Strength Revenue — 400% Increase over 4 years | Gross profit — 400% increase over 4 ars Adjusted EBITDA (Cash) positive ; q P : Self sustaining growing Business!! q ViealScopes At Rights Reserved ‘VIRTUALSCOPICS
Slide 17: PPD Alliance
PPD Alliance ter ‘cost efficiencies. ‘The partnership will provide seamless integration of technologies and processes, giving biopharmaceutical companies near real-time, consistent and reliable medical imaging information to expedite their drug development programs + “You definitely convinced me” fo
Slide 18: Personalized Medicine
Personalized Medicine ig | get an early look at the effectiveness of a patient’s treatment program. pre IDE application and anticipate 510K approval during 2011. ViealScopes At Rights Reserved
Slide 19: Employee growth
94 employees, 29% increase over 2010 terma ew employees * Building and accelerating [MM * CEO, CBFO, CTO, CSO, quality and efficiency Software, Regulatory VIRTUALSCOPICS VieualScopes At Rights Reserved
Slide 20: 2011 Imperatives
2011 Imperatives Meet Financial Goals Expansion of PPD Alli " ane Progress Personalized ea —— Imperatives Medicine Deliver Infrastructure and Technology Investments ima ¥ VIRTUALSCOPICS tive et
Slide 21: Financial & Strategic Overview
Financial & Strategic Overview a ¥ VIRTUALSCOPICS javelin FEN Molly Henderson ~~ Chief Business & Financial Officer, : Sr. Vice President
Slide 22: 2010 Financial Guidance vs. Actual
2010 Financial Guidance vs. Actual Beginning of Year Guidance | Revenues $13 million | $13.4 million | Full year gross margin 50% | 51% | Full year Adjusted EBITDA. | cen $1.5 million $2.2 million + 22% increase in full ar + Adjusted EBITDA of $2.2MM compared to $1.3MM in 2009 + $1.2 milion in cash
Slide 23: Revenues & Gross Profit — Yearly Trends
Revenues & Gross Profit — Yearly Trends AA Annual Revenues Annual Gross Profit 4x increase inf] Since inception in gross profit in 4 2001, over years, > 1005 $90MM and 270 increase in 2 years um increase in 2 years projects Steady growth in revenues and Bross profit ¥u RTUALSCOPICS sow ore Move fe:
Slide 24: Revenue composition
Revenue composition L Revenues by Study Phase revenues Mf Malorty of 2009- IM Musculoseletal inereasing revenues HA 010 growth ariven revenues due oe » by Phase III studies reduction in R&D spending by Pharma Significant growth in Oncology business since 2008 ¥u RTUALSCOPICS sow ore Move fe: Vialsco
Slide 25: Adjusted EBITDA — Yearly Trend
Adjusted EBITDA* — Yearly Trend Annual Adjusted EBITDA rong cost controls and f scale a VIRTUALSCOPICS
Slide 26: Project Balance (Backlog)
Project Balance (Backlog) as of - December 31,
Slide 27: 2011 Financial Guidance
2011 Financial Guidance Financial Area 2011 Guidance | Revenues | $16 million Full year gross margin | (ox relmbursed cost) ue | Full year Adjusted EBITDA | $1.7 million VIRTUALSCOPICS
Slide 28: First Quarter 2011 Results
First Quarter 2011 Results Financial Area $3,071k Operating Income | Gross Profit $1,600k | $1,598k Gross Margin | s rein 48% | 56% | R&D Expenditures | Stock Compensation Adjusted EBITDA
Slide 29: Personalized Medicine Application
a . we ¥ VIRTUALSCOPICS | Personalized Medicine Application
Slide 30: Supporting Information
Supporting Information Most treated patients are late stage. Waiting two months for determination of therapy efficacy could be fatal. Response rates of <30% drive the need for an early screening tool. Anti-angiogenic and vascular disruptive drugs target the newly formed blood vessels that tumor cell
Slide 31: The Answer to Anti-Angiogenesis
The Answer to Anti-Angiogenesis Effectiveness The only effective and proven Anti- response companion diagnostic approach Key Factors a ¥ VIRTUALSCOPICS
Slide 32: Dynamic Contrast-Enhanced MRI
Dynamic Contrast-Enhanced MRI (DC! Detect efficacy signal Baseline Day 2 Week 4 Week 8
Slide 33: VirtualScopics DCE-MRI Companion Diagnostic Solution
Vi p DCE-MRI C i Diagnostic Solution L Reasons to Consider PPV of other companion diagnostic. Pp ‘ection esued patent test in he market range from 60% fl creates a higher/stronger barre for (Her-2) to 80% (K-RAS) ‘others using similar technologies. vituatscoies nas conducted ow so aca ‘als using DCE
Slide 34: Regulatory Process
Regulatory Process 510k on application as a predictor of response to certain cancer therapies 510k on Collect additional application as an data to support image processing predictive nature tool of tool # Vint ALScOPICS Viealscopes AI Rights Reserved
Slide 35: Pre-IDE package sent to the FDA
Pre-IDE package sent to the FDA in February to confirm key elements of our first 510k submission, most importantly: VS Perfusion Software is Class | C Pred indicated for the post-image Absence of a suitable acquisition processing of Alternative is a predicate device would dynamic contrast-enhanced ‘
Slide 36: Next steps
Next steps ¢ File 510k ey the end of 2011 Continue to pursue partnership opportunities as a potential companion diagnostic tool and in support of FDA and Payer data requirements Develop relationships with key opinion leaders to assist in the collection of data and market option ° ViealScopes At Righ
Slide 37: 2010 Capital Markets
Yi virruaiscorics 2010 Capital Markets
Slide 38: VSCP: 2010
VSCP: 2010 ek ant L {Liss Taare 2 iA wil Viealscopes AI Rights Reserved # Vint ALScOPICS
Slide 39: Market Outreach
Market Outreach * Conference attendance * OneMed Place — San Francisco * Biolnvestor Conference — San Francisco * BioCEO — New York * Rodman & Renshaw — London * Rodman & Renshaw — New York * Added to the Russell 2000 * Two independent research analyst reports ViealScopes At Rights Reserved
Slide 40: Thank You
Thank You Question and Answer a \ VIRTUALSCOPICS ‘coin Viealscopes At Rights Reserved
Slide 41: Meeting agenda: director election and auditor ratification
Dan Kerpelman Robert Klimasewski Norman Mintz Charles Ph Terence We atify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended December 31, 2011 OMT RTUALSCOPICS Brow mere Moe fv
Slide 42: Thank You
On behalf of the VirtualScopics’ Board of Directors and Employees Thank You Vu RTUALSCOPICS row ore Moves